埃萬(wàn)妥單抗聯(lián)合療法為EGFR經(jīng)典突變晚期NSCLC提供一線治療新策略！

埃萬(wàn)妥單抗聯(lián)合蘭澤替尼重塑EGFR經(jīng)典突變晚期NSCLC一線治療格局，為患者帶來(lái)生存獲益。

*以下內(nèi)容僅供醫(yī)療衛(wèi)生專業(yè)人士瀏覽。

參考文獻(xiàn)：

[1]中國(guó)臨床腫瘤學(xué)會(huì)非小細(xì)胞肺癌專家委員會(huì),PACC專家共識(shí)編寫小組.EGFR PACC突變晚期非小細(xì)胞肺癌診療專家共識(shí)（2025版）[J].中華腫瘤雜志,2025,47(9):811-829.

[2]Cho BC,Lu S,Felip E,et al.Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.N Engl J Med.2024 Oct 24;391(16):1486-1498.

[3]Shirish MG,et al.Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC:Longer Follow-up of the MARIPOSA Study.2024 WCLC.OA.02.03.

[4]Yang JC,et al.MARIPOSA Investigators.Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.N Engl J Med.2025 Sep 7.

[5]NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines?)Non-Small cell LungCancer Version 8.2025.

[6]中國(guó)臨床腫瘤學(xué)會(huì)（CSCO）非小細(xì)胞肺癌（NSCLC）診療指南（2025年）.

[7]Lu S,Byoung CC,Jong-Seok L,et al.Amivantamab Plus Lazertinib vs Osimertinib as First-line Treatment Among Asian Patients With EGFR-mutated,Advanced Non-small Cell Lung Cancer(NSCLC):MARIPOSA Subgroup Analysis.2023 ESMO Aisa.LBA10.

[8]Felip E,et al.Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease:a secondary analysis from MARIPOSA.Ann Oncol.2024;35(9):805-816.

[9]Cho BC,Li W,Spira AI,et al.Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC:The COCOON Global Randomized Controlled Trial.J Thorac Oncol.2025 Oct;20(10):1517-1530.

[10]Spira AI,Paz-Ares L,Han JY,et al.Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr,a Phase 2 Study:A Brief Report.J Thorac Oncol.Published online January 24,2025.

審批編碼：CP-556676

批準(zhǔn)分發(fā)日期：12/9/2025

有效期：12/9/2026

*“醫(yī)學(xué)界”力求所發(fā)表內(nèi)容專業(yè)、可靠，但不對(duì)內(nèi)容的準(zhǔn)確性做出承諾；請(qǐng)相關(guān)各方在采用或以此作為決策依據(jù)時(shí)另行核查。